BioMarin Pharmaceutical Inc (BMRN): Price and Financial Metrics
BMRN Price/Volume Stats
| Current price | $88.77 | 52-week high | $108.44 |
| Prev. close | $88.30 | 52-week low | $76.02 |
| Day low | $87.85 | Volume | 1,058,200 |
| Day high | $89.49 | Avg. volume | 1,263,961 |
| 50-day MA | $93.19 | Dividend yield | N/A |
| 200-day MA | $90.04 | Market Cap | 16.72B |
BMRN Stock Price Chart Interactive Chart >
BMRN POWR Grades
- BMRN scores best on the Growth dimension, with a Growth rank ahead of 99.83% of US stocks.
- The strongest trend for BMRN is in Stability, which has been heading down over the past 26 weeks.
- BMRN ranks lowest in Momentum; there it ranks in the 18th percentile.
BMRN Stock Summary
- BMRN's current price/earnings ratio is 123.87, which is higher than 95.19% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for BMRN is currently 131.43, higher than 97.82% of US stocks with positive operating cash flow.
- In terms of volatility of its share price, BMRN is more volatile than merely 6.85% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to BIOMARIN PHARMACEUTICAL INC, a group of peers worth examining would be AGYS, BSY, MANH, PSTG, and NBIX.
- Visit BMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.biomarin.com.
BMRN Valuation Summary
- BMRN's EV/EBIT ratio is 110.9; this is 659.59% higher than that of the median Healthcare stock.
- Over the past 243 months, BMRN's EV/EBIT ratio has gone up 117.8.
Below are key valuation metrics over time for BMRN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BMRN | 2023-12-29 | 7.9 | 3.7 | 123.5 | 110.9 |
| BMRN | 2023-12-28 | 7.9 | 3.7 | 124.4 | 111.7 |
| BMRN | 2023-12-27 | 8.0 | 3.8 | 125.4 | 112.5 |
| BMRN | 2023-12-26 | 7.9 | 3.7 | 123.6 | 110.9 |
| BMRN | 2023-12-22 | 7.8 | 3.7 | 123.3 | 110.6 |
| BMRN | 2023-12-21 | 7.8 | 3.7 | 121.9 | 109.4 |
BMRN Growth Metrics
- Its 2 year revenue growth rate is now at 4.11%.
- The 4 year net income to common stockholders growth rate now stands at 120.31%.
- Its 3 year revenue growth rate is now at 23.78%.
The table below shows BMRN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 2,008.311 | 180.296 | 83.912 |
| 2022-06-30 | 1,911.709 | 119.035 | 54.07 |
| 2022-03-31 | 1,879.604 | 145.593 | 39.347 |
| 2021-12-31 | 1,846.275 | 304.536 | -64.08 |
| 2021-09-30 | 1,848.582 | 279.972 | 15.917 |
| 2021-06-30 | 1,916.624 | 269.118 | 837.214 |
BMRN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BMRN has a Quality Grade of C, ranking ahead of 36.95% of graded US stocks.
- BMRN's asset turnover comes in at 0.314 -- ranking 144th of 682 Pharmaceutical Products stocks.
- APVO, IRWD, and AVEO are the stocks whose asset turnover ratios are most correlated with BMRN.
The table below shows BMRN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.314 | 0.742 | -0.006 |
| 2021-06-30 | 0.323 | 0.707 | -0.008 |
| 2021-03-31 | 0.319 | 0.711 | -0.019 |
| 2020-12-31 | 0.338 | 0.718 | -0.003 |
| 2020-09-30 | 0.357 | 0.735 | 0.005 |
| 2020-06-30 | 0.383 | 0.782 | 0.022 |
BMRN Price Target
For more insight on analysts targets of BMRN, see our BMRN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $110.83 | Average Broker Recommendation | 1.4 (Moderate Buy) |
BioMarin Pharmaceutical Inc (BMRN) Company Bio
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU). (Source:Wikipedia)
Latest BMRN News From Around the Web
Below are the latest news stories about BIOMARIN PHARMACEUTICAL INC that investors may wish to consider to help them evaluate BMRN as an investment opportunity.
BioMarin strikes deal with Elliott, agrees to review businessUnder pressure from the activist investor, BioMarin will add more independent directors and set up an operational review committee. |
BioMarin settles with Elliott, adds 3 independent directorsBioMarin reached a settlement with activist investor Elliott Investment Management where the biotechnology company will add three independent directors to its board and form a committee to review operations. The new Strategic and Operating Review Committee will evaluate the company's business, strategy and operations, financial and capital allocation priorities, and long-term planning and priorities, the company said in a statement. In November, Reuters reported that Elliott owns a stake in BioMarin and had been holding discussions with the company, valued at $18 billion, about possible changes. |
BioMarin Announces Governance Enhancements and Value Creation InitiativesBioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation. |
Insider Sell: EVP, Chief Legal Officer George Davis Sells 13,764 Shares of Biomarin ...Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and delivering therapies for rare genetic diseases, has recently witnessed a significant insider sell by one of its top executives. |
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?Key Insights The projected fair value for BioMarin Pharmaceutical is US$193 based on 2 Stage Free Cash Flow to Equity... |
BMRN Price Returns
| 1-mo | -3.77% |
| 3-mo | 0.81% |
| 6-mo | -2.53% |
| 1-year | -18.04% |
| 3-year | 8.57% |
| 5-year | -2.08% |
| YTD | -7.93% |
| 2023 | -6.83% |
| 2022 | 17.14% |
| 2021 | 0.75% |
| 2020 | 3.71% |
| 2019 | -0.70% |
Continue Researching BMRN
Here are a few links from around the web to help you further your research on Biomarin Pharmaceutical Inc's stock as an investment opportunity:Biomarin Pharmaceutical Inc (BMRN) Stock Price | Nasdaq
Biomarin Pharmaceutical Inc (BMRN) Stock Quote, History and News - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...